Перспективы современной системы неспецифической профилактики лихорадки денге в Юго-Восточной Азии

1. World Health Organization. Disease outbreak news: Dengue outbreak in Southeast Asia. Published November 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498

2. Shepard D.S., Undurraga E.A., Halasa Y.A. Economic and disease burden of dengue in Southeast Asia. PLoS Negl. Trop. Dis. 2013; 7(2): e2055. DOI: 10.1371/journal.pntd.0002055

3. Biswal S., Reynales H., Saez-Llorens X., Lopez P., Borja-Tabora C., Kosalaraksa P. et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med. 2019; 381(21): 2009–2019. DOI: 10.1056/NEJMoa1903869

4. World Health Organization. Dengue and severe dengue. WHO Fact Sheets, 2022. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.

5. Khobragade A.W., Kadam D.D. Efficacy of tetravalent dengue vaccine: a systematic review and meta-analysis. Indian J. Community Med. 2021; 46(2): 191–194. DOI: 10.4103/ijcm.IJCM_608_20

6. Tricou V., Yu D., Reynales H., Biswal S., Saez-Llorens X., Sirivichayakul C. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob. Health. 2024; 12(2): e257–e270. DOI: 10.1016/S2214-109X(23)00522-3

7. Fernando L., Kastner R., Wickramasinghe P., Fernando A.D., Gunasekera D., Nguyen V.H. et al. Role of the dengue vaccine TAK-003 in an outbreak response: modeling the Sri Lanka experience. PLoS Negl. Trop. Dis. 2024; 18(8): e0012376. DOI: 10.1371/journal.pntd.0012376

8. Nogueira M.L., Cintra M.A.T., Moreira J.A., Patiño E.G., Braga P.E., Tenório J.C.V. et al. Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil. Lancet Infect. Dis. 2024; 24(11): 1234–1244. DOI: 10.1016/S1473-3099(24)00376-1

9. Khan M.B., Yang Z.S., Lin C.Y., Hsu M.C., Urbina A.N., Assavalapsakul W. et al. Dengue overview: an updated systemic review. J. Infect. Public Health. 2023; 16(10): 1625–1642. DOI: 10.1016/j.jiph.2023.08.001

10. Weeratunga P., Rodrigo C., Fernando S.D., Rajapakse S. Control methods for Aedes albopictus and Aedes aegypti. Cochrane Database Syst. Rev. 2017; 2017(8): CD012759. DOI: 10.1002/14651858.CD012759

11. Kamgang B., Acântara J., Tedjou A., Keumeni C., Yougang A., Ancia A. et al. Entomological surveys and insecticide susceptibility profile of Aedes aegypti during the dengue outbreak in Sao Tome and Principe in 2022. PLoS Negl. Trop. Dis. 2024; 18(6): e0011903. DOI: 10.1371/journal.pntd.0011903

12. Kongkaew C., Sakunrag I., Chaiyakunapruk N., Tawatsin A. Effectiveness of citronella preparations in preventing mosquito bites: systematic review of controlled laboratory experimental studies. Trop. Med. Int. Health. 2011; 16(7): 802–810. DOI: 10.1111/j.1365-3156.2011.02781.x

13. Most B., Pommier de Santi V., Pagès F., Mura M., Uedelhoven W.M., Faulde M.K. Long-lasting permethrin-impregnated clothing: protective efficacy against malaria in hyperendemic foci, and laundering, wearing, and weathering effects on residual bioactivity after worst-case use in the rain forests of French Guiana. Parasitol. Res. 2017; 116(2): 677–684. DOI: 10.1007/s00436-016-5333-6

14. Hossain M.J., Das M., Islam M.W., Shahjahan M., Ferdous J. Community engagement and social participation in dengue prevention: a cross-sectional study in Dhaka City. Health Sci. Rep. 2024; 7(4): e2022. DOI: 10.1002/hsr2.2022

15. Brown H., McGraw E.A. Wolbachia and mosquito vector control. Lancet Infect. Dis. 2018; 18(7): 663–671. DOI: 10.1016/S1473-3099(18)30143-0

16. Carvalho D.O., McKemey A.R., Garziera L., Lacroix R., Donnelly C.A., Alphey L. et al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl. Trop. Dis. 2015; 9(7): e0003864. DOI: 10.1371/journal.pntd.0003864

17. Ritchie S.A., Rapley L.P., Benjamin S. Bacillus thuringiensis var. israelensis (Bti) provides residual control of Aedes aegypti in small containers. Am. J. Trop. Med. Hyg. 2010; 82(6): 1053–1059. DOI: 10.4269/ajtmh.2010.09-0603

18. Carvalho K.D.S., Crespo M.M., Araújo A.P., da Silva R.S., de Melo-Santos M.A.V., de Oliveira C.M.F. et al. Long-term exposure of Aedes aegypti to Bacillus thuringiensis svar. israelensis did not involve altered susceptibility to this microbial larvicide or to other control agents. Parasit. Vectors 2018; 11(1): 673. DOI: 10.1186/s13071-018-3246-1

19. Ranathunge T., Harishchandra J., Maiga H., Bouyer J., Gunawardena Y.I.N.S., Hapugoda M. Development of the sterile insect technique to control the dengue vector Aedes aegypti (Linnaeus) in Sri Lanka. PLoS One 2022; 17(4): e0265244. DOI: 10.1371/journal.pone.0265244

20. Nazni W.A., Teoh G.-N., Nuradila M.A., Shaikh Ismail S.N.H., Tanusshni M., Muhammad Arif M.A. et al. Impact of sterile Aedes aegypti males releases on vector dynamics: insights from Malaysian field trials. Infect. Dis. Poverty. 2025; 14: 33. DOI: 10.1186/s40249-025-01303-x

21. Carrasco-Escobar G., Moreno M., Fornace K., Herrera-Varela M., Manrique E., Conn J.E. The use of drones for mosquito surveillance and control. Parasit. Vectors 2022; 15: 473. DOI: 10.1186/s13071-022-05580-5

22. Chang J., Schul W., Butters T.D., Yip A., Liu B., Goh A. et al. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011; 89(1): 26–34. DOI: 10.1016/j.antiviral.2010.11.002

23. Malinoski F.J., Hasty S.E., Ussery M.A., Dalrymple J.M. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral. Res. 1990; 13(3): 139–149. DOI: 10.1016/0166-3542(90)90029-7

24. Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Эффективность и безопасность применения препарата риамиловир в лечении пациентов с COVID-19. Антибиотики и химиотерапия 2021; 66(1–2): 35–37.

25. Козлов К.В., Мальцев О.В., Касьяненко К.В., Сукачев В.С., Саулевич А.В., Карякин С.С. и др. Оценка профилактической эффективности нуклеозидного аналога риамиловира в отношении ОРВИ у лиц из организованного коллектива. Терапевтический архив. 2024; 96(11): 1035–1041.

26. Жданов К.В., Мальцев О.В., Касьяненко К.В., Козлов К.В., Сукачев В.С., Львов Н.И. и др. Новые подходы к этиотропной терапии пациентов с ОРВИ препаратом риамиловир. Антибиотики и химиотерапия 2023; 68(9–10): 63–71.

27. Мальцев О.В., Касьяненко К.В., Жданов К.В., Малышев Н.А., Коломоец Е.В., Коному В.К. Опыт применения противовирусного препарата риамиловир у пациента с лихорадкой денге в Гвинейской Республике (клинический случай). Терапевтический архив. 2023; 95(1): 85–89.

28. Пшеничная Н.Ю., Лужецкая А.А., Коннова Ю.А., Лизенфельд И.А., Цветкова Н.А., Жданов К.В. Опыт лечения тяжелой лихорадки денге препаратом риамиловир. Инфекционные болезни. 2024; 22(2): 133–136.

29. Мальцев О.В., Козлов К.В., Дамбаев И.С., Брянская-Касьяненко К.В., Новицкий А.А., Соловьёва П.А. Использование новых подходов к комплексной терапии лихорадки денге. Инфекционные болезни. 2025; 23(2): 90–98.